English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The Leishmania donovani parasite causes visceral leishmaniasis (VL), an acute and fatal form of leishmaniasis. Because traditional therapy alternatives, such as glucantime and other pentavalent medicines, are toxic and have side effects, new treatments with fewer negative effects are needed. Only a handful of drugs are clinically beneficial to treatments of the disease, but considerable limitations threaten their very usage. Novel, safe, and efficient drugs, including those against antimalaria and leishmaniasis co-infections, are so essential. Artemether (ATM) is an Artemisinin derivative that has been demonstrated to be useful in the treatment of malaria and, more recently, leishmaniasis. The current research was carried out to evaluate the anti-leishmanial effects of Artemether (ART) and combination of Artemether- Artemisinin (ART- ATM) against procyclic promastigotes of Leishmania donovani. In this fundamental-applied research, we compared the effect of (ATM) and combination of (ART- ATM) on Leishmania donovani procyclic promastigotes, at different concentrations by using the MTT assay method after 24 ,48 and 72 h of treatment. The results prove ATM and combination (ART- ATM) efficiency against the procyclic promastigotes viability with IC50 measured after 24, 48- and 72hours treatment. The combination of (ART- ATM) could be used in the treatment of leishmaniasis to improve the therapeutic outcome for Leishmania species.

Antiparasitic activity of Artemether and combination Artemether with Artemisinin against Leishmaniasis, in vitro.